EVC
TXMD icon

Eidelman Virant Capital’s TherapeuticsMD TXMD Stock Holding History

Eidelman Virant Capital’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-1,220
Closed -$357K – 168
2015
Q3 		$357K Sell
1,220
-200
-14% -$71.1K 0.24% 90
2015
Q2 		$558K Buy
1,420
+20
+1% +$7.06K 0.25% 88
2015
Q1 		$424K Buy
+1,400
New +$342K 0.18% 100

Other funds holding TXMD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Eidelman Virant Capital's TXMD Position: Q4 2015 in Review

Eidelman Virant Capital sold out of TherapeuticsMD (TXMD) in Q4 2015, closing a stake of 1,220 shares — an estimated $357K sold.

Eidelman Virant Capital first reported a position in TXMD in Q1 2015 and held it in 3 quarters. The position peaked at $558K in Q2 2015. 123 funds tracked by Wall St. Rank hold TXMD as of Q4 2015.

  • Eidelman Virant Capital reported no remaining TherapeuticsMD position as of Q4 2015 after selling out during the quarter.
  • Eidelman Virant Capital sold 1,220 TherapeuticsMD shares in Q4 2015, an estimated $357K.
  • Eidelman Virant Capital first reported a position in TherapeuticsMD in Q1 2015 and held it in 3 quarters.
  • Eidelman Virant Capital's TherapeuticsMD position peaked at $558K in Q2 2015.
  • 123 funds tracked by Wall St. Rank held TherapeuticsMD as of Q4 2015.

Based on Eidelman Virant Capital's 13F filing for Q4 2015, filed 2 Feb 2016.